Article

Two-step approach best handles residual refractive errors

Alicante, Spain-Wavefront-guided LASIK followed 3 months later with a refinement procedure seems to be an effective method for correcting residual refractive error, according to Jorge Alio, MD, PhD, professor and chairman, department of ophthalmology, University Miguel Hernandez, Alicante, Spain.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
Related Content
Q&A: Continuum of care, the evolution of cornea, cataract, and refractive surgery
April 26th 2025

Q&A: Continuum of care, the evolution of cornea, cataract, and refractive surgery

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Scientists create a color the human eye has never seen before
April 26th 2025

Scientists create a color the human eye has never seen before

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Positive topline results from phase 2 VVN461 trial for non-infectious anterior uveitis
April 25th 2025

Positive topline results from phase 2 VVN461 trial for non-infectious anterior uveitis

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
April 25th 2025

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

© 2025 MJH Life Sciences

All rights reserved.